In vitro and in vivo equivalence studies of alendronate monosodium tablets

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 2, 2005, Pages 93-101

  Roldán, Emilio José Antonio ^a   Quattrocchi, Oscar ^a   Zanetti, Daniel ^a   Piccinni, Enrique ^a   Tessler, José ^b   Caballero, Liliana Edith ^c   Pérez Lloret, Aníbal ^c  

^a Gador SA   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c FLENI   (Argentina)

Author keywords

Alendronate, bioequivalence, dissolution test, urinary recovery; Bisphosphonates; CAS 121268 17 5; Marvil 10, bioequivalence studies; Marvil 70, bioequivalence studies

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; MARVIL 10; MARVIL 70;

ARTICLE; BIOEQUIVALENCE; BONE METABOLISM; CLINICAL TRIAL; COMMON COLD; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INTERNATIONAL COOPERATION; LONG TERM CARE; MALE; NECK PAIN; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; URINALYSIS; URINARY EXCRETION; VOMITING; XEROSTOMIA;

EID: 14744278733     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296829     Document Type: Article

References (27)

1. Fleisch, H., Bisphosphonate in bone diseases. From the laboratory to the patient. Academis Press, San Diego-London (2000)
2. Roldán, E. J. A., Quattrocchi, O., Zanchetta, J. R. et al., Comparable bioavailability of two esophago-gastric protective formulations containing pamidronate (APD). A cross-over trial in healthy young adults. Medicina (Buenos Aires) 62, 317 (2002)
3. Degrossi, O. J., Ortiz, M., Degrossi, E. B. et al., Bone scanning, serum kinetics and bioavailability of 99m Tc sodium olpadronate in patients with different bone turnover. Eur. J. Clin. Pharmacol. 48, 489 (1995)
4. Porras, A., Holland, S. D., Gertz, B. J., Pharmacokinteics of alendronate. Clin. Pharmacokinet. 36, 315 (1999)
5. Cremers, S. C. L. M., Eekhoff, E. M. E., Den Hartig, J. et al., Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosponate (olpadronate) in patients with Paget's disease of bone. J. Bone Min. Res. 18, 868 (2003)
6. Black, D. M., Thompson, D. E., Bauer, D. C. et al., Fractures risk reduction with alendronate in women with osteoporosis: The fracture intervention trial. J. Clin. Endocrinol. Metab. 85, 4118 (2000)
7. Schnitzer, T., Bone, H. G., Crepaldi, S. et al., Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin. Exp. Res. 12, 1 (2000)
8. Vega, D., Baggio, R., Garland, M. T., Monosodium 4-amino-1-hydroxy-1,1- butanediyldiphosphonate tri-hydrate (alendronate). Acta Cryst. C52, 2198 (1996)
9. Quattrocchi, O., Frisardi, L., Iglesias, M. et al., Ion exchange chromatographic determination of olpadronate, phosphate, phosphite, chloride and methanesulfonic acid. J. Pharm. Biomed. Anal. 24, 1011 (2001)
10. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, US Department of Health and Human Services, FDA, CDER, August 2000.
11. Dissolution Testing of Immediate Release Solid Oral Dosage Forms, US Department of Health and Human Services, FDA, CDER, (1997)
12. Sparidans, R. W., den Hartigh, J., Beijnen, J. H. et al., Semi-automatic liquid chromatographic analysis of pamidronate in serum and citrate plasma after derivatization with 1-naphthylisothiocyanate. J. Chromatogr. B 705, 331 (1998)
13. Sparidans, R. W., den Hartigh, J., Cremers, S. C. L. M. et al., Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate. J. Chromatogr. B 730, 95 (1999)
14. Grizzle, J. E., The two-period change-over design and its use in clinical trials. Biometrics. 21, 467 (1965) (with correction note in Biometrics. 30, 727, 1974)
15. Grizzle, J. E., The two-period change-over design and its use in clinical trials. Biometrics. 21, 467 (1965) (with correction note in Biometrics. 30, 727, 1974)
16. Chow, S. C., Liu, J. P., Design and Analysis of bioavailability and bioequivalence studies. Marcel Dekker, New York (1992)
17. Epstein, S., Cryer, B., Ragi, S. et al., Disintegration/dissolution profiles of copies of Fosamax (Alendronate) Curr. Med. Res. Opin. 19, 781 (2003)
18. Lin, I. H., Chen, I. W., DeLuna, F. A., Nonlinear kinetic of alendronate. Plasma protein binding and bone uptake. Drug Metab Disp. 22, 400 (1994)
19. Marzo, A., Balant, L. P., Bioequivalence. An update reappraisal addressed to applications of interchangeable multisource pharmaceutical products. Arzneim.-Forsch./Drug Res. 45 (I), 109 (1995)
20. Lainesse, A., Ozalp, Y., Wong, H. et al., Bioequivalence studies on bisphosphonates: the example of alendronate. Arzneim.-Forsch./Drug Res. 54 (II), 569 (2004).
21. Mitchell, D. Y., Barr, W. H., Eusebio, R. A. et al., Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm. Res. 18, 166 (2001)
22. Shah, V. P., Yacobi, A., Barr, W. H. et al., Workshop report: Evaluation of orally administered highly variable drugs and drug formulations. Pharm. Res. 13, 1590 (1996)
23. Ulla, M. R., Araujo, G. L., Giglione, F. et al., Efectos del alendronato oral, la hormonoterapia de reemplazo y la combinacion de ambos sobre la masa ósea en mujeres posmenopáusicas. Medicina (Buenos Aires) 57, 49 (1997)
24. Weisinger, J. R., Alonzo, E., Machado, C. et al., Papel del hueso en la fisiopatología de la hipercalciuria idiopática. Medicina (Buenos Aires) 57, 45 (1997)
25. Oh, H. J., Choi, H. J., Kim, E. H. et al., Effects of combination therapy of Alend® & HRT for postmenopausal osteoporotic Korean women; 1-year result. J. Korean Osteopor. Assoc. 8, 49, (2001)
26. Negri, A., Roldán, E. J. A., Short-term compliance to daily alendronate treatment in 1875 patients with osteoporosis. The ECMO study. J Bone Miner Res. 16 (Suppl.), 407 (2001)
27. Negri, A. L., Roldán, E. J. A., Daily and weekly alendronate compliance: A south American experience. Osteoporosis Int. 15 (Suppl. 1), S87 (2004)